Home › NDC Lookup › Ingredients › Levothyroxine Sodium › 47781-0721-90
⚪image loading
(from DailyMed)

levothyroxine sodium 112 ug Tablet, 90-count — NDC 47781-721-90 (Billing 47781-0721-90)

by Alvogen, Inc. · 90 TABLET in 1 BOTTLE

This is a package of 90 tablets of levothyroxine sodium 112 ug Tablet from Alvogen, Inc., marketed since May 2019 and currently FDA-listed; retail pharmacies pay about $0.0588 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 47781-0721-90
🏷️ FDA NDC (as labeled) 47781-721-90 billing pads the product segment with a zero
This package
Contains90-count Cost per ea$0.0588 NADAC Per package$5.29 / 90 tablets Pack sizes2 compare ↓
Main listing for product 47781-721 · Also comes in: 1000 tablets 47781-721-10
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 47781-721-90 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
47781 labeler · 721 product · 90 package
Package marketed since
Aug 19, 2026
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
90 EA per package
Barcode (UPC-A, from the NDC)
3 4778172190 9
FDA record last changed
Oct 8, 2026
🚨
Active recall for this product.
Class II · Dec 31, 2025 — Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets. (Alvogen, Inc) · FDA recall D-0259-2026
Lots / codes: Lot # MHA21825, Exp Date: December 31, 2027 · reported Jan 21, 2026
Check your lot/expiration against the official notice — look up the recall number in the FDA recall database ↗
⚠️
Other active recalls for Levothyroxine Sodium (different manufacturers) — 6 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Aug 6, 2026 — Subpotent Drug (ACCORD HEALTHCARE, INC.) · FDA recall D-0776-2026
Class II · Aug 6, 2026 — Subpotent Drug (ACCORD HEALTHCARE, INC.) · FDA recall D-0781-2026
Class II · Aug 6, 2026 — Subpotent Drug (ACCORD HEALTHCARE, INC.) · FDA recall D-0775-2026
Class II · Aug 6, 2026 — Subpotent Drug (ACCORD HEALTHCARE, INC.) · FDA recall D-0782-2026
Class II · Aug 6, 2026 — Subpotent Drug (ACCORD HEALTHCARE, INC.) · FDA recall D-0786-2026
Class II · Aug 6, 2026 — Subpotent Drug (ACCORD HEALTHCARE, INC.) · FDA recall D-0780-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 47781-721-90
Product NDC 47781-721
11-digit billing NDC 47781072190
NCPDP billing unit EA — each (per item)
Application # NDA021116
SPL Set ID 3b8c38aa-ac99-1c0d-42f3-4fe8881125dc
Established class (EPC) l-Thyroxine
Chemical class Thyroxine
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2019-05-07
Route ORAL
Dosage form TABLET
Substance LEVOTHYROXINE SODIUM
TE code (Orange Book) AB1,AB2,AB3,AB4 · RLD · RS
Why two NDCs? The FDA registers this code as 47781-721-90 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 47781-0721-90. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

📖 What it is MedlinePlus · NLM

Levothyroxine is used to treat hypothyroidism (condition where the thyroid gland does not produce enough thyroid hormone). It is also used with surgery and radioactive iodine therapy to treat thyroid cancer. Levothyroxine is in a class of medications called hormones. It works by replacing thyroid hormone that is normally produced by the body. Without thyroid hormone, your body cannot function properly, which may result in poor growth, slow speech, lack of energy, excessive tiredness, constipation, weight gain, hair loss, dry, thick skin, increased sensitivity to cold, joint and muscle pain, he...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It replaces thyroid hormone when your thyroid doesn’t make enough, a condition called hypothyroidism. Oral forms are also used with surgery and radioiodine for certain thyroid canc...
  • Oral forms are usually taken once a day on an empty stomach, about 15 to 60 minutes before breakfast, depending on the product. Keep calcium, iron and antacids at least 4 hours awa...
  • Full effect may take 4 to 6 weeks. Your doctor will check TSH and/or T4 blood tests to adjust your dose.
  • No. It doesn’t cause weight loss at normal doses if your thyroid is normal. Larger doses can be seriously toxic.
📖 Read our full Levothyroxine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.059 $5.29 / 90 tablets
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Sep 2026 $0.059 $0.059
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
47781-0721-90 You're viewing this Main listing 90 TABLET in 1 BOTTLE $0.0588 / ea $5.29 2026-08-19 — Active
47781-0721-10 47781-721-10 1000 TABLET in 1 BOTTLE — — 2026-09-22 — Active

You're viewing the smallest of 2 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This is a 90-count package — 90 tablet in 1 bottle.
How does this package differ from NDC 47781-0721-10?
Both are levothyroxine sodium 112 ug Tablet — the drug itself is identical. This page's package is the 90-count one, while NDC 47781-0721-10 is the 1000 tablets package.
What NDC number is used to bill for this package of levothyroxine sodium 112 ug Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Levothyroxine sodium 112 ug 16729-0452-15 Accord 90 tablets $0.059 AB1,AB2,AB3,AB4 Availability likely —
Levo-T 112 ug 55466-0109-11 Neolpharma, 90 tablets $0.059 AB1,AB2,AB3 Discontinued —
Levothyroxine Sodium 112 ug 72603-0665-01 NorthStar 1000 tablets $0.059 AB1,AB2,AB3,AB4 Availability likely —
Levothyroxine Sodium 112 ug 42292-0039-20 Mylan 100 tablets $0.059 AB1,AB2,AB3,AB4 Availability likely —
Levothyroxine Sodium 112 ug 33342-0398-10 Macleods 90 tablets $0.059 AB1,AB2,AB3,AB4 Availability likely —
levothyroxine sodium 112 ug 47781-0654-10 Alvogen, 1000 tablets $0.059 AB1,AB2,AB3,AB4 Availability likely —
Levothyroxine Sodium 112 ug 00378-1811-10 Mylan 1000 tablets $0.059 AB1,AB2,AB3,AB4 Availability likely —
Levothyroxine Sodium 112 ug 00527-3285-43 Lannett 1000 tablets $0.059 AB1,AB2,AB3 Availability likely —
levothyroxine sodium 112 ugthis 47781-0721-90 Alvogen, 90 tablets $0.059 AB1,AB2,AB3,AB4 Availability likely —
Euthyrox 112 ug 72305-0112-30 Provell 30 tablets $0.147 — Discontinued +149%
Levoxyl 112 ug 60793-0855-01 Pfizer 100 tablets $1.116 AB1,AB3 Availability likely +1799%
Synthroid 112 ug 00074-9296-19 AbbVie 1000 tablets $1.660 AB1,AB2 Availability likely +2724%
Unithroid 112 ug 60846-0806-01 Amneal 100 tablets $4.208 AB1,AB2,AB3 Availability likely +7057%
levothyroxine sodium 112 ug 68788-7697-01 Preferred 100 tablets — AB1,AB2,AB3,AB4 FDA listed —
Levothyroxine sodium 112 ug 68788-7942-01 Preferred 100 tablets — AB1,AB2,AB3,AB4 FDA listed —
Levothyroxine sodium 112 ug 50090-6103-00 A-S 90 tablets — AB1,AB2,AB3,AB4 FDA listed —
Levothyroxine Sodium 112 ug 51655-0604-52 Northwind 30 tablets — AB1,AB2,AB3,AB4 FDA listed —
Levothyroxine sodium 112 ug 87063-0088-00 ASCLEMED 1000 tablets — AB1,AB2,AB3,AB4 FDA listed —
Levothyroxine Sodium 112 ug 63629-2088-01 Bryant 1000 tablets — AB1,AB2,AB3 FDA listed —
Levothyroxine sodium 112 ug 70518-4396-00 REMEDYREPACK 90 tablets — AB1,AB2,AB3,AB4 FDA listed —
levothyroxine sodium 112 ug 71335-1465-01 Bryant 30 tablets — AB1,AB2,AB3,AB4 FDA listed —
Levothyroxine Sodium 112 ug 72162-1091-00 Bryant 1000 tablets — AB1,AB2,AB3 FDA listed —
Levothyroxine sodium 112 ug 50090-7526-00 A-S 90 tablets — AB1,AB2,AB3,AB4 FDA listed —
Levothyroxine Sodium 112 ug 71335-1955-01 Bryant 30 tablets — AB1,AB2,AB3 FDA listed —
Levothyroxine sodium 112 ug 71335-2007-01 Bryant 30 tablets — AB1,AB2,AB3,AB4 FDA listed —
Levothyroxine Sodium 112 ug 72189-0159-30 DIRECT 30 tablets — AB1,AB2,AB3,AB4 FDA listed —
Levothyroxine Sodium 112 ug 72189-0605-90 Direct_Rx 90 tablets — AB1,AB2,AB3,AB4 FDA listed —
Levothyroxine sodium 112 ug 50090-7527-00 A-S 90 tablets — AB1,AB2,AB3,AB4 FDA listed —
Levothyroxine Sodium 112 ug 51655-0579-52 Northwind 30 tablets — AB1,AB2,AB3 FDA listed —
Levothyroxine sodium 112 ug 00480-8704-01 Teva 100 tablets — AB1,AB2,AB3,AB4 Discontinued —
Levothyroxine sodium 112 ug 50090-6602-00 A-S 90 tablets — AB1,AB2,AB3,AB4 FDA listed —
Levothyroxine Sodium 112 ug 50090-8065-00 A-S 90 tablets — AB1,AB2,AB3,AB4 FDA listed —
About this product: this is the brand-name version. FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2019
On the market since
May 2019
📍
2026
Currently FDA-listed
7 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Levothyroxine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAlvogen, Inc.
Application holderALVOGEN INC
FDA applicationNDA021116 (NDA)
Labeler code47781
First marketedMay 2019
Product typeHuman Prescription Drug
Portfolio32 products on file

More NDCs from Alvogen, Inc. labeler code 47781

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Levothyroxine Sodium — the program that covers self-administered drugs. 19 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Levothyroxine Sodium. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$118.86M
Claims incl. refills
10.9M
Beneficiaries
7.8M
Spend / beneficiary
$15.20
Spend / claim
$10.88
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 47781-0690-30 · Alvogen, 47781-0728-90 · Alvogen, →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.